Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.
- DOI
- 10.1016/j.vaccine.2026.128871
- Published
- 2026-07-03
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128871,
title = {Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.},
author = {Nakano T and Iwata S and Oishi K and Iguchi E and Suganuma Y and Tada Y and Saiki S and Hashimoto K and Nakajima-Yoshida H and Omoto S and Yazaki T and Sonoyama T.},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128871},
url = {https://doi.org/10.1016/j.vaccine.2026.128871}
}RIS
TY - JOUR TI - Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study. AU - Nakano T AU - Iwata S AU - Oishi K AU - Iguchi E AU - Suganuma Y AU - Tada Y AU - Saiki S AU - Hashimoto K AU - Nakajima-Yoshida H AU - Omoto S AU - Yazaki T AU - Sonoyama T. PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128871 UR - https://doi.org/10.1016/j.vaccine.2026.128871 ER -
APA
T, N., S, I., K, O., E, I., Y, S., Y, T., S, S., K, H., H, N., S, O., T, Y., & T., S. (2026). Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128871
Source records
- europe-pmc · retrieved 2026-09-26T05:51:53.404Z